Loading...
•
Sep 30, 2022
Supernus Q3 2022 Earnings Report
Reported a 19% increase in total revenues compared to Q3 2021.
Key Takeaways
Supernus Pharmaceuticals, Inc. announced financial results for the third quarter of 2022. Total revenues increased by 19% compared to the same period in 2021. The company is raising its full-year 2022 operating earnings and total revenues guidance. Qelbree prescriptions and net product sales continued to grow.
Total revenues for Q3 2022 were $177.4 million, a 19% increase compared to Q3 2021.
Qelbree prescriptions in Q3 2022 reached 94,328, a 50% increase compared to Q2 2022.
Qelbree net product sales in Q3 2022 were $18.3 million, a 65% increase compared to Q2 2022.
GOCOVRI net product sales in Q3 2022 were $27.9 million, a 16% increase compared to net product sales reported by Adamas in Q3 2021.
Revenue by Segment
Forward Guidance
The Company is raising the midpoint and narrowing the expected ranges of full year 2022 financial guidance for total revenues and operating earnings (GAAP).
Positive Outlook
- Total revenues are expected to be between $650 million and $680 million.
- Combined R&D and SG&A expenses are expected to be between $460 million and $475 million.
- Operating earnings are expected to be between $35 million and $45 million.
- Amortization of intangible assets is projected to be between $80 million and $84 million.
- Non-GAAP operating earnings are projected to be between $135 million and $155 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...